Greenwich Lifesciences, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders1 buying, 0 selling12 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
- Funds31 adding, 26 cuttingOf 4 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 18% in the quarter to 2026-06-30, the 2nd beat in the last four quarters.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Greenwich Lifesciences, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Volatile shares. Over the past year the shares showed annualised volatility of 105% and a beta of 3.3 against the S&P 500.
- Heavily shorted. 20.3% of the shares available to trade are sold short (11.0 days of average volume to cover).
- Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.
Latest results
- Earnings per share
- -$0.27 against an average estimate of -$0.33: beat by 18.2%
- Next report
- November 12, 2026
Price chart
- 1 day-5.5%
- 1 week-3.9%
- 1 month-3.1%
- This year-21.7%
- 1 year+78.7%
- 5 years-55.1%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for GLSI from the sources we follow. See filings →
No model value for Greenwich Lifesciences, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Valuation models
We value Greenwich Lifesciences, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.4%: the 10-year Treasury yield (4.9%) plus a beta of 1.2 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Greenwich Lifesciences, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 12, 2026, after the close. Analysts expect revenue of $0 for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$1.39 | +3% | — | 0% |
| Next | −$1.17 | +16% | — | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is +2.6% on 90 days ago. In the last 30 days, 0 analysts raised Greenwich Lifesciences, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year |
|---|---|
| 90 days ago | −$1.35 |
| 60 days ago | −$1.35 |
| 30 days ago | −$1.48 |
| 7 days ago | −$1.48 |
| Now | −$1.39 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.33 | −$0.27 | +18.2% |
| Mar 2026 | −$0.35 | −$0.39 | −11.4% |
| Dec 2025 | −$0.32 | −$0.58 | −81.2% |
| Sept 2025 | −$0.36 | −$0.30 | +16.7% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 20.3% of tradable shares
- Days to cover
- 11.01 at average volume
- Short interest, 1 month
- −5% to October 15, 2026
- Held by institutions
- 12% of shares
- Held by insiders
- 47.9% of shares
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| GLSI | −33% | −38% | −31% | +7% | +87% | −22% |
| Industry peers (median) | −36% | −57% | −17% | −29% | −5% | −27% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| GLSI | 42% | 50% | 25% | 50% | 42% | 36% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| GLSI | −59% | −71% | −63% | −46% | −43% | −62% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since September 25, 2020: 90% from December 10, 2020 to June 16, 2022. Getting back needed a 912% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $7.85 – $33.56
- From 52-week high
- −51.0%
- vs 50-day average
- −1.7%
- vs 200-day average
- −23.4%
- Volatility (1 year)
- 105%
- Beta vs S&P 500
- 3.32
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $39.6M
- Institutions reporting
- 58
- Shares held vs prior quarter
- ▼ 1.5%
- Positions opened / closed
- 8 / 11
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Blackrock, Inc. | $11.4M | 486K | 28.8% | ▲ 12.0% |
| Vanguard Capital Management LLC | $6.5M | 278K | 16.5% | ▼ 6.7% |
| Geode Capital Management, LLC | $3.9M | 168K | 10.0% | ▲ 8.2% |
| State Street Corp | $3.4M | 143K | 8.5% | ▲ 6.9% |
| Vanguard Portfolio Management LLC | $1.9M | 81K | 4.8% | ▲ 37.3% |
| Northern Trust Corp | $1.9M | 80K | 4.8% | ▲ 6.8% |
| Bank Of New York Mellon Corp | $1.1M | 48K | 2.8% | ▲ 3.0% |
| Vanguard Fiduciary Trust Co | $1.1M | 46K | 2.7% | ▲ 2.4% |
| Morgan Stanley | $1M | 43K | 2.6% | ▲ 45.7% |
| Goldman Sachs Group Inc | $922,658 | 39K | 2.3% | ▼ 0.5% |
| Russell Investments Group, Ltd. | $805,939 | 34K | 2.0% | ▼ 13.5% |
| Jane Street Group, LLC | $649,701 | 28K | 1.6% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Greenwich Lifesciences, Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Patel Snehal CEO and CFO | July 29, 2026 | Buy | 700 | $13.10 | $9,170 |
| Patel Snehal CEO and CFO | July 28, 2026 | Buy | 1,500 | $13.59 | $20,385 |
| Patel Snehal CEO and CFO | July 27, 2026 | Buy | 1,500 | $13.62 | $20,430 |
| Patel Snehal CEO and CFO | July 24, 2026 | Buy | 1,100 | $12.88 | $14,168 |
| Patel Snehal CEO and CFO | July 23, 2026 | Buy | 2,500 | $13.14 | $32,850 |
| Patel Snehal CEO and CFO | January 13, 2026 | Buy | 1,800 | $29.83 | $53,694 |
| Patel Snehal CEO and CFO | January 12, 2026 | Buy | 2,900 | $27.54 | $79,866 |
| Patel Snehal CEO and CFO | December 31, 2025 | Buy | 4,300 | $21.36 | $91,848 |
| Patel Snehal CEO and CFO | December 30, 2025 | Buy | 2,900 | $21.73 | $63,017 |
| Patel Snehal CEO and CFO | December 18, 2025 | Buy | 4,100 | $12.62 | $51,742 |
| Patel Snehal CEO and CFO | November 25, 2025 | Buy | 4,600 | $8.37 | $38,502 |
| Patel Snehal CEO and CFO | November 7, 2025 | Buy | 10,600 | $8.43 | $89,358 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Recent SEC filings
- DEF 14A Proxy statement
- 10-Q Quarterly report
- 10-Q Quarterly report
- 10-K Annual report
- 8-K Current report
- 10-Q Quarterly report
- DEF 14A Proxy statement
- 10-Q Quarterly report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Greenwich Lifesciences, Inc. in brief
- What does Greenwich Lifesciences, Inc. do?
- Greenwich Lifesciences, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Greenwich Lifesciences, Inc.'s stock ticker?
- Greenwich Lifesciences, Inc. trades under the ticker GLSI on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Greenwich Lifesciences, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Vanguard Capital Management LLC and Geode Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Greenwich Lifesciences, Inc. stock?
- Over the last 12 months, Greenwich Lifesciences, Inc.'s directors and officers reported 12 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
- When is Greenwich Lifesciences, Inc.'s next earnings date?
- Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Greenwich Lifesciences, Inc. announces its own schedule.
Follow research on Greenwich Lifesciences, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.